London, 22 January 2015 – The Global Atrial Fibrillation Market is expected to grow at a CAGR of 11.05 percent from 2014-2019, says research firm TechNavio.
About the Report
According to the latest report by TechNavio, vendors are increasingly focusing on emerging markets, as developing economies offer a large base of clinical trial subjects, as well as customers. Factors like lenient regulatory guidelines, low manufacturing costs, skilled labor and limited competition in the market are also leading to a decrease in development costs for medical devices and an increase in the profit margins of manufacturers.
“In the BRIC countries, growing GDP and increased public awareness have promoted the acceptance of medical technologies for the detection and treatment of atrial fibrillation,” says Faisal Ghaus, Vice President of TechNavio.
The TechNavio report also emphasizes the increased awareness among patients, their families and caregivers that is expected to increase the acceptance of various drugs, thus increasing the penetration of drugs in the market. Additionally, the use of generics in the treatment of atrial fibrillation is also becoming popular in developing and emerging countries.
“The low price of generics compared to branded prescription drugs has increased their popularity in many emerging markets like India, Bangladesh, Brazil and China,” says Ghaus.
Key Information Covered in the Report:
Market segmentation, size and forecast through 2019
Market Growth Drivers:
- Increase in Patient Population
- For a full detailed list, view our report.
Market Challenges:
- High Cost of Treatment
- For a full detailed list, view our report.
Market Trends:
- Growing Focus on Emerging Markets
- For a full detailed list, view our report.
Key Vendors:
- Boehringer Ingelheim GmbH
- Janssen Pharmaceuticals Inc.
- Sanofi SA
Other Prominent Vendors:
- ARCA Biopharma
- Armetheon
- Baxter
- Daiichi Sankyo
https://www.technavio.com/%3Cp%3E%3Ca%20href%3D%22http%3A//www.technavio….
